EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Association of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics and Hemorrhage Risk Factors in Patients With Venous Thromboembolism

Hui Li iD, Xiaoshuang He, Yingyun Guan iD, Qiuya Lu, Jie Fang, Xiaolan Bian iD

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.040698 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Hui Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Ruijin Hospital, Shanghai Jiaotong University School of Medicine Shanghai China. Hauptthemen laut MEDLINE: Rivaroxaban, Venous Thromboembolism, Factor Xa Inhibitors, Hemorrhage. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rivaroxaban is a first‐line agent for venous thromboembolism prophylaxis and treatment. However, its pharmacokinetics, pharmacodynamics, and bleeding risk exhibit significant interindividual variability. Known nongenetic factors alone cannot fully explain this variability, and the impact of genetic polymorphisms remains debated.

Methods

From December 29, 2021, to May 11, 2023, 310 patients with venous thromboembolism treated with rivaroxaban were enrolled in this observational study from a tertiary hospital in Shanghai, China, based on predefined criteria. We assessed relationships between rivaroxaban concentrations, anti‐Factor Xa levels, and coagulation parameters; examined the impact of 12 genes on concentrations and anti‐Factor Xa levels; and followed up for at least 3 months to identify bleeding risk factors.

Results

Rivaroxaban plasma concentration was significantly related to anti‐Factor Xa levels (R 2 =0.697), activated partial thromboplastin time (R 2 =0.134), prothrombin time (R 2 =0.123), and international normalized ratio (R 2 =0.116). Peak concentrations were associated with cytochrome p450 3A5 (rs776746, P =0.023), sushi domain‐containing protein 3 ( rs76292544, P =0.034), and ATP‐binding cassette subfamily G member 2 ( rs1045642, P =0.012); trough concentrations were linked to cytochrome p450 3A5 (rs776746, P =0.045), sushi domain‐containing protein 3 (rs76292544, P =0.014), and ATP‐binding cassette subfamily G member 2 (rs2231142, P =0.029); peak anti‐Factor Xa levels were associated with aldo‐keto reductase family 7 member A3 (rs1738023, P =0.022; rs1738025, P =0.035) and ATP‐binding cassette subfamily A member 6 (rs7212506, P =0.044). However, these genetic associations were not significant after Bonferroni correction. Hemorrhage risk factors were anemia, pulmonary embolism, and the TT genotype of sushi domain‐containing protein 3 (rs76292544).

Conclusions

Pharmacogenetic monitoring and hemorrhage risk assessment may contribute to optimize its efficacy and safety. Larger‐scale, global multicenter clinical trials are required to validate the potential gene loci for testing, including cytochrome p450 3A5 (rs776746), sushi domain‐containing protein 3 (rs76292544), ATP‐binding cassette transporter B1 (rs1045642), and ATP‐binding cassette subfamily G member 2 (rs2231124), with particular focus on sushi domain‐containing protein 3 (rs76292544).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanVenous ThromboembolismFactor Xa InhibitorsHemorrhagePharmacogenomic VariantsHumansMaleFemaleMiddle AgedRisk FactorsAgedChinaRisk AssessmentBlood CoagulationCytochrome P-450 CYP3APolymorphism, Single Nucleotide

Stichwörter der Autor:innen

anti‐FXa levelgene polymorphismshemorrhagepharmacokinetics and pharmacodynamicsrivaroxaban

Substanzen

RivaroxabanFactor Xa InhibitorsCytochrome P-450 CYP3A

Autor:innen und Institutionen

  • Department of Pharmacy Ruijin Hospital, Shanghai Jiaotong University School of Medicine Shanghai China.
  • Department of Laboratory Medicine Ruijin Hospital, Shanghai Jiaotong University School of Medicine Shanghai China.

ORCID-Profile: Hui Li, Yingyun Guan, Xiaolan Bian

Zitieren

APA

Li, H., He, X., Guan, Y., Lu, Q., Fang, J., & Bian, X. (2025). Association of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics and Hemorrhage Risk Factors in Patients With Venous Thromboembolism. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040698

Vancouver

Li H, He X, Guan Y, Lu Q, Fang J, Bian X. Association of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics and Hemorrhage Risk Factors in Patients With Venous Thromboembolism. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040698

BibTeX
@article{Li2025,
  author = {Li, Hui and He, Xiaoshuang and Guan, Yingyun and Lu, Qiuya and Fang, Jie and Bian, Xiaolan},
  title = {Association of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics and Hemorrhage Risk Factors in Patients With Venous Thromboembolism},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.040698}
}
Kostenlos starten →